In recent trading session, Adma Biologics Inc (NASDAQ:ADMA) saw 0.74 million shares changing hands at last check today with its beta currently measuring 0.45. Company’s recent per share price level of $18.45 trading at $0.05 or 0.30% at last check today assigns it a market valuation of $4.41B. That most recent trading price of ADMA’s stock is at a discount of -39.13% from its 52-week high price of $25.67 and is indicating a premium of 44.66% from its 52-week low price of $10.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.19 million shares which gives us an average trading volume of 3.56 million if we extend that period to 3-months.
For Adma Biologics Inc (ADMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Upright in the green today for gaining 0.30%, in the last five days ADMA remained trading in the green while hitting it’s week-highest on Friday, 06/27/25 when the stock touched $18.45 price level, adding 0.65% to its value on the day. Adma Biologics Inc’s shares saw a change of 67.62% in year-to-date performance and have moved 4.03% in past 5-day. Adma Biologics Inc (NASDAQ:ADMA) showed a performance of -5.41% in past 30-days. Number of shares sold short was 13.81 million shares which calculate 5.43 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a fall of -15.31% to its recent value today. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 24.12% in reaching the projected high whereas dropping to the targeted low would mean a gain of 24.12% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 27.15% while estimates for its earnings growth in next 5 years are of 39.37%.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders are in possession of 2.58% of company’s total shares while institution are holding 88.42 percent of that, with stock having share float percentage of 90.76%. Investors also watch the number of corporate investors in a company very closely, which is 88.42% institutions for Adma Biologics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ADMA for having 18.64 million shares of worth $208.45 million. And as of 2024-06-30, it was holding 8.0221 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 14.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.2459 of outstanding shares, having a total worth of $162.3 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025 , the former fund manager was holding 14.34 shares of worth $262.09 million or 6.01% of the total outstanding shares. The later fund manager was in possession of 6.34 shares on Mar 31, 2025 , making its stake of worth around $115.93 million in the company or a holder of 2.66% of company’s stock.
